| Identification | Back Directory | [Name]
3,3'-(2,4-Diamino-6,7-pteridinediyl)bisphenol | [CAS]
677297-51-7 | [Synonyms]
CS-427 100-115 TG100-115, >=98% TG100115; TG100 115 TG100-115;TG100115;TG100 115 3,3,-(2,4-diaminopteridine-6,7-diyl)diphenol 3,3'-(2,4-Diamino-6,7-pteridinediyl)bispheno 3,3'-(2,4-Diamino-6,7-pteridinediyl)bisphenol 6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine Phenol, 3,3'-(2,4-diamino-6,7-pteridinediyl)bis- 3,3'-(2,4-Diamino-6,7-pteridinediyl)bisphenol TG100-115 | [Molecular Formula]
C18H14N6O2 | [MDL Number]
MFCD16038873 | [MOL File]
677297-51-7.mol | [Molecular Weight]
346.3 |
| Chemical Properties | Back Directory | [Boiling point ]
699.6±65.0 °C(Predicted) | [density ]
1.516±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
insoluble in H2O; insoluble in EtOH; ≥3.46 mg/mL in DMSO | [form ]
Yellow powder solid. | [pka]
8.54±0.10(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
TG100-115 is a potent and selective phosphoinositide 3-kinase gamma/delta (PI3Kγ/δ) inhibitor. It can provide potent cardioprotection, reduce infarct development, and preserve myocardial function. | [Definition]
ChEBI: 3-[2,4-diamino-7-(3-hydroxyphenyl)-6-pteridinyl]phenol is a member of pteridines. | [Biological Activity]
tg100-115 is an inhibitor of pi3kγ and pi3kδ with ic50 values of 83 nm and 235 nm, respectively. tg100-115 shows no obvious activity against pi3kα and pi3kβ [1].tg100-115 remarkably reduced eosinophil accumulation, balf levels of classic th2 cytokine il-13, perivascular and peribronchial leukocyte accumulations, and bronchiolar mucin accumulation in a murine model. besides, tg100-115 showed to reduce airway hyper-responsiveness (ahr) by approximately 50% in asthmatic mice. moreover, tg100-115 has been reported to reduce both smoke-and lps-induced neutrophil and lps-induced classic th1 cytokine tnfα accumulations in mice [2]. | [in vivo]
To correlate these in vivo responses with the molecular target of interest, PI3K pathway signaling is monitored through western blot analyses of Akt phosphorylation (a PI3K-mediated event). VEGF injection i.v. in mice induces a rapid Akt phosphorylation readily detectable in lung lysates, pretreatment with TG100-115 blocks this response. Blockade is seen with TG100-115 doses as low as 0.5 mg/kg and persists over a period of several hours. In initial dose-ranging studies, generally equivalent responses are observed using TG100-115 doses of 0.5-10 mg/kg, and we therefore elected to conduct a statistically powered test at the lowest dose. Animals dosed with TG100-115 as a single 0.5 mg/kg i.v. bolus 30 min after reperfusion developed smaller infarcts vs. vehicle-treated controls. Measuring infarct area as percent of total LV ischemic area, infarct size is reduced by 35% (P=0.04). Viable tissue within the ischemic zone is increased by 37% (P=0.04), directly demonstrating the cardioprotective effect of PI3Kγ/δ inhibition[1]. | [target]
PI3K-γ | [IC 50]
PI3Kγ: 83 nM (IC50); PI3Kδ: 235 nM (IC50) | [References]
[1] doukas j1, wrasidlo w, noronha g, dneprovskaia e, fine r, weis s, hood j, demaria a, soll r, cheresh d. hosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. proc natl acad sci u s a. 2006 dec 26;103(52):19866-71. [2] doukas j1, eide l, stebbins k, racanelli-layton a, dellamary l, martin m, dneprovskaia e, noronha g, soll r, wrasidlo w, acevedo lm, cheresh da. aerosolized phosphoinositide 3-kinase gamma/delta inhibitor tg100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. j pharmacol exp ther. 2009 mar;328(3):758-65. |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Telephone: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
|